Skip to main content

Thermo Fisher Records Mighty Q2 Revenue, Profit Growth

NEW YORK (GenomeWeb News) — Thermo Fisher Scientific today said second-quarter revenues increased 236 percent as R&D spending rose 44 percent and profit increased over 240 percent.
 
Total receipts for the three months ended June 30 increased to $2.4 billion from $714 million year over year. Last year's results reflect Thermo Electron's operations prior to its merger with Fisher Scientific in November. Including both firm's results from last year, second-quarter revenues increased 9 percent year over year.
 
Thermo said revenue from its Analytical Technologies segment nearly doubled to just over $1 billion, while receipts from the Laboratory Products and Services segment increased to $1.43 billion from $182 million. On a pro forma basis, Analytical Technologies revenue grew 13 percent, while revenue for the Lab Products and Services segment grew 6 percent.
 
“We've now delivered three strong quarters as Thermo Fisher Scientific, clearly demonstrating that we are successfully operating as one company,” CEO Marijn Dekkers said in a statement.
 
Dekkers attributed the growth to strong demand for new products, “healthy end markets and our combined operating discipline.”
 
R&D spending increased to $58.7 million from $40.7 million in the second quarter of 2006.
 
The company said profit rose to $164 million from $48 million in the year-ago period.
 
Thermo Fisher said it had around $951 million in cash and cash equivalents and $22.7 million in short-term investments as of June 30.
 
Dekkers said the company is increasing its revenue guidance to a range of $9.5 billion to $9.55 billion for 2007, from the $9.4 billion to $9.5 billion previously announced.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.